Agios Pharmaceuticals (NASDAQ:AGIO) Research Coverage Started at HC Wainwright

HC Wainwright assumed coverage on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research note issued to investors on Monday morning, MarketBeat reports. The firm issued a buy rating and a $58.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q1 2025 earnings at ($1.53) EPS, Q2 2025 earnings at ($1.61) EPS, Q3 2025 earnings at ($1.40) EPS, Q4 2025 earnings at ($1.42) EPS, FY2025 earnings at ($6.40) EPS, FY2026 earnings at ($7.35) EPS, FY2027 earnings at ($8.37) EPS, FY2028 earnings at ($7.33) EPS and FY2029 earnings at ($5.53) EPS.

Several other research analysts have also weighed in on AGIO. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Scotiabank boosted their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Finally, Royal Bank of Canada upped their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO opened at $34.44 on Monday. Agios Pharmaceuticals has a one year low of $27.14 and a one year high of $62.58. The business has a fifty day moving average price of $33.92 and a 200 day moving average price of $42.86. The company has a market cap of $1.97 billion, a P/E ratio of 3.04 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, sell-side analysts predict that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 363 shares during the period. Summit Investment Advisors Inc. raised its holdings in Agios Pharmaceuticals by 7.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company’s stock valued at $194,000 after acquiring an additional 394 shares in the last quarter. Federated Hermes Inc. lifted its stake in Agios Pharmaceuticals by 4.4% in the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 582 shares during the last quarter. KBC Group NV grew its holdings in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 611 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Agios Pharmaceuticals by 6.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock valued at $539,000 after purchasing an additional 688 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.